№ lp_1_2_51007
File format: docx
Character count: 7266
File size: 4695 KB
Public health communication material outlining background data, key messages, vaccination schedules, and ready-to-use informational content regarding the MMR vaccine within the UK childhood immunisation programme.
Year:
2022
Region:
London, United Kingdom
Topic:
Childhood immunisation
Vaccine:
MMR (measles, mumps, rubella)
Type of document:
Public health communication toolkit
Health system:
NHS
Target population:
Parents and carers of children aged 1–5 years
Vaccination schedule:
1 year (first dose), 3 years and 4 months (second dose)
Key threshold:
95% coverage for herd immunity
Related organisations:
NHS, UK medicines and vaccines regulator, Oxford University Vaccine Knowledge Project
Format:
Overview with key messages, resources, Q&A, and sample communication content
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / city:
London, UK
Topic:
Immunization, MMR vaccine
Document type:
Informational guide
Organization / institution:
NHS
Author:
Public Health England
Target audience:
Parents, caregivers
Effective period:
Ongoing
Approval date:
N/A
Date of updates:
N/A
Year:
2024
Region / City:
Victoria, Australia
Topic:
Immunisation
Document Type:
Official Information
Author:
Department of Health, State of Victoria
Target Audience:
Healthcare professionals, parents, and individuals requiring immunisation information
Period of Validity:
Not specified
Approval Date:
August 2024
Date of Changes:
Not specified
Note:
Year
Topic:
Vaccination Consent
Document Type:
Consent Form
Target Audience:
Patients, Healthcare Providers
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Year:
2025
Region / City:
London
Topic:
Neonatal BCG vaccination program
Document Type:
Protocol
Organization / Institution:
NHSE
Author:
Alice Waters
Target Audience:
Healthcare professionals involved in neonatal care and immunization
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
September 2025
Year:
2023
Region / City:
N/A
Subject:
Vaccination
Document Type:
Medical Guidelines
Organization / Institution:
Merck
Author:
N/A
Target Audience:
Healthcare professionals
Effective Period:
N/A
Approval Date:
07/13/2015
Revision Dates:
07/13/2015, 11/15/2015, 06/2016, 04/2023, 08/2024
Year:
2025
Region / city:
United Kingdom
Subject:
COVID-19 vaccination
Document type:
Protocol
Institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare providers involved in COVID-19 vaccination
Period of validity:
1 October 2025 – 31 January 2026
Approval date:
12 September 2025
Note:
Revision history
Year:
2025
Region / city:
[insert local health board name]
Theme:
Vaccination
Document type:
Patient Group Direction (PGD)
Authorising organisation:
NHS Wales
Target audience:
Healthcare professionals (Registered)
Period of validity:
01 September 2025 - 31 March 2026
Approval date:
07 August 2025
Amendment date:
30 June 2025
Review date:
01 July 2026
Expiry date:
31 March 2026
Year:
2025
Region / city:
England
Topic:
Influenza immunisation
Document type:
Patient Group Direction (PGD)
Organisation:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Jamie Lopez-Bernal, Greta Hayward
Target audience:
Healthcare practitioners, NHS organisations
Period of validity:
From 1 September 2025 to 1 April 2026
Approval date:
3 July 2025
Revision history:
Updated annually, latest update 9 July 2025
Reference no:
HPV (GBMSM) PGD
Version no:
v5.0
Valid from:
1 September 2025
Review date:
1 April 2028
Expiry date:
1 September 2028
Author:
Suki Hunjunt, Sharif Ismail, David Green
Region / city:
England
Target audience:
Healthcare practitioners administering HPV vaccine to GBMSM
Type of document:
Patient Group Direction
Organisation:
UK Health Security Agency (UKHSA)
Date of approval:
17 July 2025
Date of modifications:
16 July 2025
Context:
A formal Patient Group Direction for the administration of HPV vaccine to GBMSM, detailing legal, clinical, and procedural requirements for healthcare practitioners in England.
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Region / city:
Global
Topic:
Vaccine Policy, Maternal Health, Group B Streptococcus
Document type:
WHO Guidance
Institution:
World Health Organization (WHO)
Author:
WHO ECVP
Target audience:
Policymakers, Vaccine Developers, Public Health Authorities
Period of validity:
Ongoing
Approval date:
March 11, 2025
Date of changes:
Not specified
Year:
2025
Region:
England
Subject:
Hepatitis B vaccination for renal patients
Document Type:
Patient Group Direction (PGD)
Authorising Organisation:
UK Health Security Agency (UKHSA)
Target Audience:
Registered healthcare professionals
Period of Validity:
28 February 2025 - 28 February 2028
Approval Date:
28 February 2025
Amendment Date:
21 February 2025
Year:
2024
Region / city:
England
Topic:
Vaccination
Document type:
Patient Group Direction
Organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Mary Ramsay, David Green
Target audience:
Registered healthcare practitioners
Period of validity:
10 October 2024 - 30 April 2027
Approval date:
4 October 2024
Amendments date:
9 October 2024
Year:
2018
Region / City:
Oregon
Theme:
Vaccine Replacement, Immunization Policy
Document Type:
Policy
Organization:
Oregon Immunization Program (OIP)
Target Audience:
VFC program organizations, Healthcare providers
Period of Action:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Document type:
Regulatory template appendix
Subject:
Quality information summary for finished pharmaceutical products and vaccines
Procedure:
Reference SRA collaborative procedure
Regulatory framework:
WHO Guidelines on submission of documentation for prequalification
Issuing organization:
World Health Organization
Series:
WHO Technical Report Series
Series number:
No. 1010
Year:
2018
Scope:
Pharmaceutical products and vaccines approved by stringent regulatory authorities
Intended use:
National registration under the SRA collaborative procedure
Confidentiality status:
Includes confidential quality information
Approval basis:
Information as approved by the reference SRA
Change management:
Revision required upon approved variations affecting QIS-SRA (crp)
Year:
2021
Region / City:
United States
Topic:
COVID-19 Vaccine, Long Term Care, Health and Safety Regulations
Document Type:
Guide
Organization:
Centers for Medicare & Medicaid Services (CMS), Centers for Disease Control and Prevention (CDC)
Author:
Centers for Medicare & Medicaid Services (CMS), Centers for Disease Control and Prevention (CDC)
Target Audience:
Long Term Care Facility Leaders, Healthcare Providers, Staff
Period of Action:
2021
Approval Date:
November 2021
Date of Last Revision:
October 26, 2022
Year:
2018
Region / City:
New Zealand
Theme:
Risk Management, Food Safety
Document Type:
Toolkit
Organization:
Ministry for Primary Industries
Author:
Ministry for Primary Industries
Target Audience:
RMP operators, Food Industry professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Ongoing updates, no fixed date
Year:
2013
Region:
North West England
Topic:
Healthcare, Emergency Medicine, Haemorrhage Management
Document Type:
Guideline
Organization:
North West Regional Transfusion Committee (NW RTC)
Authors:
Steering group of NW RTC Major Haemorrhage Guidelines Group
Target Audience:
Healthcare professionals involved in transfusion and emergency care
Effective Period:
Ongoing
Approval Date:
December 2013
Revision Date:
June 2013
Year:
2025
Region / City:
London
Theme:
Mental Health, Asylum Seekers, Refugees, Wellbeing Support
Document Type:
Communication Toolkit
Organization / Institution:
Thrive LDN
Author:
Thrive LDN team
Target Audience:
Professionals, Practitioners, Local Authorities, NHS, Community and Voluntary Sector
Period of Activity:
March to May 2025
Approval Date:
November 18, 2025
Date of Last Revision:
Not specified
Context:
Promotional pack designed to help London’s professionals and practitioners share information about the new Signpost wellbeing email service for asylum seekers and refugees.